KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer

Bingbing Dai, Suk Young Yoo, Geoffrey Bartholomeusz, Ryan A. Graham, Mourad Majidi, Shaoyu Yan, Jieru Meng, Lin Ji, Kevin Coombes, John D. Minna, Bingliang Fang, Jack A. Roth

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Intrinsic resistance to agents targeting phosphoinositide 3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibitor MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide siRNA library screening and biologic characterization, we identi fied that inhibition of thioredoxin reductase-1 (TXNRD1), one of the key antioxidant enzymes, with siRNAs or its inhibitor, aurano fin, sensitized NSCLC cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive oxygen species production, which was involved in c-jun-NH2-kinase (JNK; MAPK8) activation and cell apoptosis. Furthermore, we found that the synthetic lethality interaction between the TXNRD1 and AKT pathways occurred through the KEAP1/NRF2 cellular antioxidant pathway. Finally, we found that synthetic lethality induced by TXNRD1 and AKT inhibitors relied on wild-type KEAP1 function. Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and aurano fin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.

Original languageEnglish (US)
Pages (from-to)5532-5543
Number of pages12
JournalCancer Research
Volume73
Issue number17
DOIs
StatePublished - Sep 1 2013

Fingerprint

Thioredoxin Reductase 1
Lung Neoplasms
Antioxidants
Non-Small Cell Lung Carcinoma
MAP Kinase Kinase 4
Phase II Clinical Trials
Clinical Trials, Phase I
1-Phosphatidylinositol 4-Kinase
United States Food and Drug Administration
Small Interfering RNA
Reactive Oxygen Species
Biomarkers
Synthetic Lethal Mutations
Genome
Apoptosis
Mutation
Enzymes
Pharmaceutical Preparations
Genes
MK 2206

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dai, B., Yoo, S. Y., Bartholomeusz, G., Graham, R. A., Majidi, M., Yan, S., ... Roth, J. A. (2013). KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Research, 73(17), 5532-5543. https://doi.org/10.1158/0008-5472.CAN-13-0712

KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. / Dai, Bingbing; Yoo, Suk Young; Bartholomeusz, Geoffrey; Graham, Ryan A.; Majidi, Mourad; Yan, Shaoyu; Meng, Jieru; Ji, Lin; Coombes, Kevin; Minna, John D.; Fang, Bingliang; Roth, Jack A.

In: Cancer Research, Vol. 73, No. 17, 01.09.2013, p. 5532-5543.

Research output: Contribution to journalArticle

Dai, B, Yoo, SY, Bartholomeusz, G, Graham, RA, Majidi, M, Yan, S, Meng, J, Ji, L, Coombes, K, Minna, JD, Fang, B & Roth, JA 2013, 'KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer', Cancer Research, vol. 73, no. 17, pp. 5532-5543. https://doi.org/10.1158/0008-5472.CAN-13-0712
Dai B, Yoo SY, Bartholomeusz G, Graham RA, Majidi M, Yan S et al. KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. Cancer Research. 2013 Sep 1;73(17):5532-5543. https://doi.org/10.1158/0008-5472.CAN-13-0712
Dai, Bingbing ; Yoo, Suk Young ; Bartholomeusz, Geoffrey ; Graham, Ryan A. ; Majidi, Mourad ; Yan, Shaoyu ; Meng, Jieru ; Ji, Lin ; Coombes, Kevin ; Minna, John D. ; Fang, Bingliang ; Roth, Jack A. / KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer. In: Cancer Research. 2013 ; Vol. 73, No. 17. pp. 5532-5543.
@article{0ab797f3e1e04466b49c9ad269eb7389,
title = "KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer",
abstract = "Intrinsic resistance to agents targeting phosphoinositide 3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibitor MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide siRNA library screening and biologic characterization, we identi fied that inhibition of thioredoxin reductase-1 (TXNRD1), one of the key antioxidant enzymes, with siRNAs or its inhibitor, aurano fin, sensitized NSCLC cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive oxygen species production, which was involved in c-jun-NH2-kinase (JNK; MAPK8) activation and cell apoptosis. Furthermore, we found that the synthetic lethality interaction between the TXNRD1 and AKT pathways occurred through the KEAP1/NRF2 cellular antioxidant pathway. Finally, we found that synthetic lethality induced by TXNRD1 and AKT inhibitors relied on wild-type KEAP1 function. Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and aurano fin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.",
author = "Bingbing Dai and Yoo, {Suk Young} and Geoffrey Bartholomeusz and Graham, {Ryan A.} and Mourad Majidi and Shaoyu Yan and Jieru Meng and Lin Ji and Kevin Coombes and Minna, {John D.} and Bingliang Fang and Roth, {Jack A.}",
year = "2013",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-13-0712",
language = "English (US)",
volume = "73",
pages = "5532--5543",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - KEAP1-dependent synthetic lethality induced by AKT and TXNRD1 inhibitors in lung cancer

AU - Dai, Bingbing

AU - Yoo, Suk Young

AU - Bartholomeusz, Geoffrey

AU - Graham, Ryan A.

AU - Majidi, Mourad

AU - Yan, Shaoyu

AU - Meng, Jieru

AU - Ji, Lin

AU - Coombes, Kevin

AU - Minna, John D.

AU - Fang, Bingliang

AU - Roth, Jack A.

PY - 2013/9/1

Y1 - 2013/9/1

N2 - Intrinsic resistance to agents targeting phosphoinositide 3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibitor MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide siRNA library screening and biologic characterization, we identi fied that inhibition of thioredoxin reductase-1 (TXNRD1), one of the key antioxidant enzymes, with siRNAs or its inhibitor, aurano fin, sensitized NSCLC cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive oxygen species production, which was involved in c-jun-NH2-kinase (JNK; MAPK8) activation and cell apoptosis. Furthermore, we found that the synthetic lethality interaction between the TXNRD1 and AKT pathways occurred through the KEAP1/NRF2 cellular antioxidant pathway. Finally, we found that synthetic lethality induced by TXNRD1 and AKT inhibitors relied on wild-type KEAP1 function. Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and aurano fin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.

AB - Intrinsic resistance to agents targeting phosphoinositide 3-kinase (PI3K)/AKT pathway is one of the major challenges in cancer treatment with such agents. The objective of this study is to identify the genes or pathways that can be targeted to overcome the resistance of non-small cell lung carcinoma (NSCLC) to the AKT inhibitor MK2206, which is currently being evaluated in phase I and II clinical trials. Using a genome-wide siRNA library screening and biologic characterization, we identi fied that inhibition of thioredoxin reductase-1 (TXNRD1), one of the key antioxidant enzymes, with siRNAs or its inhibitor, aurano fin, sensitized NSCLC cells to MK2206 treatment in vitro and in vivo. We found that simultaneous inhibition of TXNRD1 and AKT pathways induced robust reactive oxygen species production, which was involved in c-jun-NH2-kinase (JNK; MAPK8) activation and cell apoptosis. Furthermore, we found that the synthetic lethality interaction between the TXNRD1 and AKT pathways occurred through the KEAP1/NRF2 cellular antioxidant pathway. Finally, we found that synthetic lethality induced by TXNRD1 and AKT inhibitors relied on wild-type KEAP1 function. Our study indicates that targeting the interaction between AKT and TXNRD1 antioxidant pathways with MK2206 and aurano fin, a U.S. Food and Drug Administration-approved drug, is a rational strategy to treat lung cancer and that KEAP1 mutation status may offer a predicative biomarker for such combination approaches.

UR - http://www.scopus.com/inward/record.url?scp=84883471209&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883471209&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-0712

DO - 10.1158/0008-5472.CAN-13-0712

M3 - Article

C2 - 23824739

AN - SCOPUS:84883471209

VL - 73

SP - 5532

EP - 5543

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -